Neoadjuvant Immunoradiotherapy With Evorpacept and Pembrolizumab in HPVOPC (Human Papilloma Virus Oropharynx Cancer)

Running, not enrolling · Phase 2

Conditions studied: Oropharynx Cancer

In brief

The majority of head and neck cancer patients do not respond to immunotherapies, and clinical responses are often not durable. However, targeting tumors with stereotactic radiation in combination with immunotherapy while sparing draining lymphatics enhances anticancer immunity, resulting in dramatic response in HPV (Human Papilloma Virus) virus related cancers of the throat. This trial will leverage targeted tumor radiation and immunotherapy in advance of standard surgical therapy to improve the response of HPV (Human Papilloma Virus) throat cancer to radiation and immunotherapy.

Key facts

Study ID

NCT05787639

Run by

University of California, San Diego

People needed

28

Starts

2024-02-23

Expected to finish

2029-10-01

Last updated by the study team

2026-07-16

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histologically confirmed diagnosis of Stage I T1-2N1M0 HPVOPC (Human Papilloma Virus Oropharynx Cancer)
• Amenable to surgical resection
• Are able to safely receive neoadjuvant radiation and Evorpacept/Pembrolizumab

You may not qualify if…

• Patients with solitary lymph nodes less than 3 cm

Where it is running

• UC San Diego Moores Cancer Center — La Jolla, California, United States
• Providence Health & Services — Portland, Oregon, United States
• Oregon Health and Science University — Portland, Oregon, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.